Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06769126 · ClinicalTrials.gov registry record · Phase 2

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

A Phase 2 study of Extensive Stage Lung Small Cell Carcinoma and Lung Small Cell Carcinoma, A Subtype, sponsored by SWOG Cancer Research Network.

Recruiting
Registry status
Phase 2
Development phase
900
Enrollment target
20
Study locations

NCT06769126 is a Phase 2 study of Extensive Stage Lung Small Cell Carcinoma and Lung Small Cell Carcinoma, A Subtype that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 900 participants, above the 95-participant average among 16 other Extensive Stage Lung Small Cell Carcinoma trials with a reported enrollment target (847% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06769126, a Phase 2 study of Extensive Stage Lung Small Cell Carcinoma and Lung Small Cell Carcinoma, A Subtype, is actively recruiting participants, sponsored by SWOG Cancer Research Network.

RECRUITING
Registry status
Phase 2
Development phase
900 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.

Conditions Studied

Extensive Stage Lung Small Cell Carcinoma Lung Small Cell Carcinoma, A Subtype Lung Small Cell Carcinoma, I Subtype Lung Small Cell Carcinoma, N Subtype Lung Small Cell Carcinoma, P Subtype

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • BIOLOGICAL Durvalumab
  • DRUG Etoposide
  • DRUG Ceralasertib

Study Locations (20)

Iowa

  • Mary Greeley Medical Center - Ames
  • McFarland Clinic - Ames - Ames
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic - Ankeny
  • McFarland Clinic - Boone - Boone
  • Mercy Hospital - Cedar Rapids
  • Oncology Associates at Mercy Medical Center - Cedar Rapids
  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic - Clive
  • Iowa Methodist Medical Center - Des Moines
  • UI Health Care Mission Cancer and Blood - Des Moines Clinic - Des Moines
  • Mercy Medical Center - Des Moines - Des Moines
  • UI Health Care Mission Cancer and Blood - Laurel Clinic - Des Moines
  • McFarland Clinic - Trinity Cancer Center - Fort Dodge
  • McFarland Clinic - Jefferson - Jefferson
  • McFarland Clinic - Marshalltown - Marshalltown

Idaho

  • Kootenai Health - Coeur d'Alene - Coeur d'Alene
  • Kootenai Clinic Cancer Services - Post Falls - Post Falls
  • Kootenai Clinic Cancer Services - Sandpoint - Sandpoint

Delaware

  • Helen F Graham Cancer Center - Newark
  • Medical Oncology Hematology Consultants PA - Newark

Illinois

  • Loyola University Medical Center - Maywood

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2025-11-06
Est. Completion 2029-12-31
Phase Phase 2

Sponsor

SWOG Cancer Research Network

270 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06769126

The ClinicalTrials.gov registry entry for NCT06769126 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 95-participant average among 16 other Extensive Stage Lung Small Cell Carcinoma trials with a reported enrollment target (847% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Extensive Stage Lung Small Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06769126 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Iowa, Idaho, Delaware.

Frequently Asked Questions

What is clinical trial NCT06769126 about?

NCT06769126 is a clinical study titled "Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study". This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is dr...

What is the current status of trial NCT06769126?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 900 participants. The study started on 2025-11-06. Estimated completion is 2029-12-31.

What conditions does trial NCT06769126 study?

This clinical trial studies the following conditions: Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype.

What interventions are being tested in trial NCT06769126?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Durvalumab (BIOLOGICAL), Etoposide (DRUG), Ceralasertib (DRUG).

Who is sponsoring clinical trial NCT06769126?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06769126 being conducted?

This trial has 20 study locations across Delaware, Idaho, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive Stage Lung Small Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Extensive Stage Lung Small Cell Carcinoma

All registered trials for this condition

Lung Small Cell Carcinoma, A Subtype

All registered trials for this condition

Delaware

All trials with a study site in Delaware

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.